Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This Phase I research study is to test the effects (good and bad) and best dose of BT062 in
treating patients with relapsed or refractory multiple myeloma.